Perrigo gets FDA approval for over-the-counter equivalents to GSK's nicotine gum
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Essential IR Insights Newsletter - Summer July-August 2023
Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits
Perrigo Co. PLC received approvals from the U.S. FDA for abbreviated new drug applications referencing GlaxoSmithKline PLC's Nicorette White Ice Mint Gum, a nicotine chewing gum.
These products will be packaged and marketed as store brands or retailers' own label brands to bring alternatives to the GSK product.
Annual sales of Nicorette White Ice Mint Gum for the 12 months ending November were $79 million.
